Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 1/2 1Phase 1 1

Status

Unknown 8Recruiting 7Completed 7Not yet recruiting 6Terminated 5Active not recruiting 1

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 7

Sponsor

Cancer Type

Gastrointestinal 7Genitourinary 1

Conditions

Colorectal Neoplasms 50Neoplasms 13Neoplasm Metastasis 12Gastrointestinal Stromal Tumors 10Carcinoma, Hepatocellular 7Glioblastoma 5Colonic Neoplasms 5Sarcoma 4Stomach Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Liver Neoplasms 3Rhabdomyosarcoma 2Rectal Neoplasms 2Pancreatic Neoplasms 2Gallbladder Neoplasms 2Esophageal Neoplasms 2Colorectal Cancer Metastatic 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Bile Duct Neoplasms 2Advanced Cancer 2Wilms Tumor 1Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer) 1Thymoma 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Solid Tumor 1Sarcoma, Ewing 1

Interventions

Sorafenib 121Nivolumab 36pembrolizumab 32Bevacizumab 28lenvatinib 27Doxorubicin 23Radiosurgery 21Radiofrequency Ablation 20Oxaliplatin 20Hepatectomy 18Fluorouracil 15Capecitabine 15Magnetic Resonance Spectroscopy 14atezolizumab 13Leucovorin 13Cisplatin 13Gemcitabine 11Erlotinib Hydrochloride 11tislelizumab 9Sirolimus 9Radiotherapy 9Irinotecan 9Ipilimumab 9cabozantinib 8Liver Transplantation 8regorafenib 7Ramucirumab 7Folfox protocol 7Embolization, Therapeutic 7sintilimab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Completed × Carcinoma, Hepatocellular × regorafenib × Clear all
NCT04696055 2025-05-13

Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors

Bayer

Phase 2 Completed
95 enrolled 14 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04170556 2024-09-03

GOING

Fundacion Clinic per a la Recerca Biomédica

Phase 1/2 Completed
69 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03890731 2024-04-02

A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed

Bayer

Phase 2 Completed
6 enrolled 11 charts
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT03347292 2023-07-25

Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC

Bayer

Phase 1 Completed
58 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04310709 2022-12-06

RENOBATE

Asan Medical Center

Phase 2 Completed
42 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01774344 2020-08-20

RESORCE

Bayer

Phase 3 Completed
573 enrolled 23 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT01003015 2015-04-03

Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma

Bayer

Phase 2 Completed
36 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡